Covidien aquires Barrx - thoughts?

Quote

Anonymous

Guest
Curious what any of you might be able to tell me what a post-Covidien acquired Barrx might look like?

How does Covidien treat acquisitions such as this? Move in and change the culture, system, process, etc; or invest, and sit back and watch the company grow?

Also - how would you describe your career with Covidien? Is this the type of place where people build careers, or is it a 3-5 year and move-on type of job?

Any serious responses or insight would be appreciated.

The Endoscopy lab is a much different place than the OR, so I'm not sure if a comparison to the typical Covidian experience applies??

Thanks.
 






I can't speak for the acquisition but Covidien is an incredible place to build a career. The pay isn't always the highest but the culture, wealth of opportunities and total benefits package are as good as any.
 












Years ago, Covidien (formerly US Surgical and Valleylab) was a great place to gain experience in the OR for a few years and then use the name to land a nice career elsewhere. Now Covidien hires kids with no sales experience and college grads. The majority of the sales force is awful and the management is a bunch of mediocre brown nosing insecure idiots with no leadership.

The turnover is quite high. I personally know over 10 people who have left the company in the past year. The veteran sales reps that are still there aren't skilled enough to land a better job and are happy with the status quo. Covidien will turn this acquisition into another train wreck, then it will simply be come another item # in their catalog.
 






























I had my fears when Covidien acquired ev3 where I was working at the time. But given our high growth prospects vis-a-vis the general surgery portfolio, we have basically been given as much freedom as one could ever expect (with the added benefit of $$ infusion we wouldn't have seen as ev3 standalone). Given that Barrx is a therapy and not just a OR surgical tool, I think the same growth prospect argument will make sure that leadership keeps the Barrx mgmt in place for a while and pump in extra capital to accelerate growth. So I think you are in a very good position as a Barrx employee...
 






Bared has significant issues with their technology, Cov would be smart to compliment with CSA.
Bared has lost blue cross coverage in my state, not sure if that has gotten better or worse over the country.
Cov has the size to open doors that Barrx couldn't-for those that stay, u may b very happy!
 


















A previous blogger stated that Barrx's technology was insufficient and Covidien should also purchase CSA. What does CSA offer that Barrx does not? Are they able to treat multiple conditions whereas Barrx is only used to treat Barret's esophagus? Any other additional information would be great, thanks for the help!!
 






Anonymous said:
A previous blogger stated that Barrx's technology was insufficient and Covidien should also purchase CSA. What does CSA offer that Barrx does not? Are they able to treat multiple conditions whereas Barrx is only used to treat Barret's esophagus? Any other additional information would be great, thanks for the help!!
Click to expand...

CSA? You're joking right? CSA and their therapy isn't widely accepted nor utilized. COV won't drop a dime on a long shot like CSA. COV wants proven profitable winners, not some wanna be, me too therapy.
 






Top Bottom
Back
Quote